Bayesian Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bayesian Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-62,300	Closed	-$374K	–	1190
2022 Q4	$374K	Buy	+62,300	New	+$340K	0.05%	426
2022 Q3	–	Sell	-52,200	Closed	-$312K	–	1112
2022 Q2	$312K	Buy	+52,200	New	+$267K	0.06%	470
2016 Q3	–	Sell	-1,620	Closed	-$6K	–	616
2016 Q2	$6K	Sell	1,620 -5,990	-79%	-$27.5K	﹤0.01%	385
2016 Q1	$40K	Buy	+7,610	New	+$60.8K	0.04%	335

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bayesian Capital Management's CTIC Position: Q1 2023 in Review

Bayesian Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 62,300 shares — an estimated $374K sold.

Bayesian Capital Management first reported a position in CTIC in Q1 2016 and held it in 4 quarters. The position peaked at $374K in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Bayesian Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Bayesian Capital Management sold 62,300 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $374K.
Bayesian Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2016 and held it in 4 quarters.
Bayesian Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $374K in Q4 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Bayesian Capital Management's 13F filing for Q1 2023, filed 15 May 2023.